Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.45 |
| ▸ | CDK2 | P24941 | 8/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 2/20 | 0.44 |
| ▸ | WEE1 | P30291 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3450155 | 0.81 | SELP (0.48) | MAPK1CDK2MAPKAPK2EGFR | |
| SCHEMBL3447819 | 0.81 | SELP (0.48) | MAPK1CDK2MAPKAPK2EGFR | |
| SCHEMBL3449528 | 0.81 | SELP (0.48) | MAPK1CDK2MAPKAPK2EGFR | |
| SCHEMBL657412 | 0.79 | MAPK1 (0.62) | MAPK1CDK2EGFRAURKAAPP | |
| SCHEMBL4621510 | 0.75 | MAPK1 (0.61) | MAPK1EGFRAPP | |
| SCHEMBL3214863 | 0.74 | PLK4 (0.69) | AURKBAURKA | |
| SCHEMBL3197568 | 0.74 | MAPK1 (0.73) | MAPK1CDK2EGFRAURKAAPP | |
| SCHEMBL1391901 | 0.74 | APP (0.58) | MAPK1CDK2MAPKAPK2ROCK2MAPK9 | |
| SCHEMBL3451208 | 0.74 | EGFR (0.44) | EGFR | |
| SCHEMBL3447987 | 0.74 | EGFR (0.44) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | IDH1 718/4885MAPK1 2905/4885CDK2 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.